Earnings Buzz and Reactions: Accolade, Progress Software, and Nike
- June 29th, 2023
- 502 views
Accolade, Inc. (Nasdaq: ACCD) released its first-quarter fiscal 2024 earnings report, revealing a loss of $0.52 per share, which was better than the consensus estimate of a loss of $0.62 per share. The company also reported quarterly sales of $93.20 million, surpassing the consensus expectation of $90.30 million.
Encouraged by these results, Accolade raised its full-year fiscal year 2024 revenue guidance to a range of $410 million to $414 million, which exceeds the consensus estimate of $409.93 million for the period.
$ACCD was trading at $14.58 in after-hours, marking a significant increase of $1.94 (15.35%).
In other news, Progress Software Corporation (Nasdaq: PRGS) announced its second-quarter fiscal 2023 earnings, reporting an EPS of $1.06, outperforming the consensus estimate of $0.90. Looking ahead to the third quarter of fiscal 2023, the company projects an EPS in the range of $0.98 to $1.02, compared to the consensus estimate of $0.97 for the period.
Additionally, Progress Software raised its full-year fiscal 2023 EPS guidance to a range of $4.16 to $4.24, up from the previous range of $4.09 to $4.17. This adjustment exceeds the consensus estimate of $4.14 for the period.
In after-hours, $PRGS was trading at $55.02, showing a gain of $0.14 (0.26%).
Separately, Nike, Inc. (NYSE: NKE) released its fourth-quarter fiscal 2023 earnings report, disclosing an EPS of $0.66, slightly below the consensus estimate of $0.67. However, the company's quarterly sales reached $12.82 billion, surpassing the consensus estimate of $12.59 billion.
$NKE was trading at $109.90, down $3.47 (3.06%) in after-hours.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)
Post Your Comments
Want To Find Some News?
Recent Posts
-
Treasury Targets Family Members and Associates of Maduro Regime
December 20th, 2025Herbal Works Inc. Supports President Trump's Order Easing Restriction on Cannabis
December 18th, 2025Herbal Works Inc. Plans on Expansion of Product Line in 2026
December 18th, 2025December 17th, 2025Crown Equity Holdings Inc. Announces Changes to Board of Directors
December 16th, 2025




Member Login